ArticleThe Lancet regional health. Southeast Asia2026
Long term outcomes of the Indian childhood cancer survivorship (C2S) cohort: a multicentre study (2016-2024).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Almost 90% of childhood cancers occur in lower income- and middle-income countries (LMICs) like India, leading to a growing population of cancer survivors. However, data on long-term outcomes and late effects are limited. The Indian Childhood Cancer Survivorship (C2S) Study was envisaged to build a nationwide survivor cohort and systematically capture treatment exposures and long-term outcomes. Methods: The C2S study is a prospective multicentric observational cohort initiated in 2016 under the Indian Pediatric Hematology Oncology Group (InPOG-LE-16-01). Children diagnosed with cancer before 18 years of age and in remission post-treatment were enrolled. Demographic, clinical, and treatment exposure data were collected at respective centres and monitored centrally. Follow-up was conducted every three months, assessing survival, relapse, and abandonment rates. Findings: As of December 2024, the study includes data from 20 centres across India with 5419 survivors being enrolled, with survival data available for 5140. Acute leukemia was the most common diagnosis (40.9%). Common therapeutic exposures included chemotherapy (94.7%), surgery (30.3%), and radiotherapy (26.3%). The 5-year overall survival (OS) and event-free survival (EFS) rates for the entire cohort were 94.5% (95% CI: 93.7-95.3)% and 89.9% (95% CI: 88.8-91.0)%, respectively. For the 2266 survivors with ≥2 years post-treatment follow-up, 5 y-OS and EFS were 98.2 (95% CI: 97.5-98.7)% and 95.7 (95% CI: 94.7-96.6)%, respectively. Interpretation: The C2S study represents the first structured attempt to build a nationwide childhood cancer survivors' cohort in India. This cohort will serve as a denominator for future research on late effects, support the development of survivorship guidelines, and inform policy planning in India and comparable LMIC settings. Funding: There was no dedicated funding for this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.